A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
Status:
RECRUITING
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .